SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 YTD Q2 P&L / Income Statement

SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Revenue categories. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

1,132,054,000 US dollars

Total cost and expenses

760,330,000 US dollars

Operating income (loss)

371,724,000 US dollars

Other income (expense), net (calculated)

negative 30,299,000 US dollars

(Loss) income before income tax expense (benefit)

341,425,000 US dollars

Income tax expense (benefit)

15,356,000 US dollars

Net (loss) income

326,069,000 US dollars

Products, net

659,204,000 US dollars

Collaboration and other

472,850,000 US dollars

Cost of sales (excluding amortization of in-licensed rights)

258,153,000 US dollars

Research and development

245,218,000 US dollars

Selling, general and administrative

216,551,000 US dollars

Litigation contingency charge

39,000,000 US dollars

Amortization of in-licensed rights

1,408,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.